Mức độ miR-30c trong huyết thanh dự đoán độc tính trên tim ở bệnh nhân ung thư phổi không tế bào nhỏ điều trị bằng Bevacizumab

Siegel, R., et al. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29. Iyer, S., et al. (2014). The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Supportive Care in Cancer, 22(1), 181–187. Gridelli, C., et al. (2007). The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. The Oncologist, 12(10), 1183–1193. Lauro, S., et al. (2014). The use of bevacizumab in non-small cell lung cancer: An update. Anticancer Research, 34(4), 1537–1545. Ding, L., et al. (2014). The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumor Biology, 36(4), 2491–2499. Kruzliak, P., Novak, J., & Novak, M. (2014). Vascular endothelial growth factor inhibitor-induced hypertension: From pathophysiology to prevention and treatment based on long-acting nitric oxide donors. American Journal of Hypertension, 27(1), 3–13. Choueiri, T. K., et al. (2011). Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology, 29(6), 632–638. Yeung, S. L., Lam, H. S., & Schooling, C. M. (2017). Vascular endothelial growth factor and ischemic heart disease risk: A mendelian randomization study. Journal of the American Heart Association, 6(8), e005619. Hueso, L., et al. (2017). Dynamics and implications of circulating anti-angiogenic VEGF-A165b isoform in patients with ST-elevation myocardial infarction. Scientific Reports, 7(1), 9962. Wang, X., et al. (2017). Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Experimental and Therapeutic Medicine, 14(2), 1399–1408. Sandhu, H., & Maddock, H. (2014). Molecular basis of cancer-therapy-induced cardiotoxicity: Introducing microRNA biomarkers for early assessment of subclinical myocardial injury. Clinical Science, 126(6), 377–400. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297. Lawrence, P., & Ceccoli, J. (2017). Advances in the application and impact of MicroRNAs as therapies for skin disease. BioDrugs, 31(5), 423–438. Pallez, D., Gardes, J., & Pasquier, C. (2017). Prediction of miRNA-disease associations using an evolutionary tuned latent semantic analysis. Scientific Reports, 7(1), 10548. Hirt, M. N., et al. (2015). Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. Journal of Molecular and Cellular Cardiology, 81, 1–9. Hou, Y., et al. (2012). Beta-adrenoceptor regulates miRNA expression in rat heart. Medical Science Monitor, 18(8), BR309–BR314. Bao, J. L., & Lin, L. (2014). MiR-155 and miR-148a reduce cardiac injury by inhibiting NF-kappaB pathway during acute viral myocarditis. European Review for Medical and Pharmacological Sciences, 18(16), 2349–2356. Lagos-Quintana, M., et al. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735–739. Abonnenc, M., et al. (2013). Extracellular matrix secretion by cardiac fibroblasts: Role of microRNA-29b and microRNA-30c. Circulation Research, 113(10), 1138–1147. Yanaihara, N., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3), 189–198. Panizo, S., et al. (2017) Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrology Dialysis Transplantation, 32(11), 1831–1840 Martín, M., et al. (2009). Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. The Oncologist, 14(1), 1–11. Cakmak, H., et al. (2017). Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Cutaneous and Ocular Toxicology, 37(2), 191–195. Ferrara, N., Hillan, K. J. & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 333(2), 328–335. Giordano, F. J., et al. (2001). A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proceedings of the National Academy of Sciences of the United States of America, 98(10), 5780–5785. Hong, I. H., & Park, S. P. (2017). Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases. Indian Journal of Ophthalmology, 65(7), 559–568. Deuse, T., et al. (2009). Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation, 120(11 Suppl), S247–S254. Liu, X., et al. (2016). miR-30c regulates proliferation, apoptosis and differentiation via the Shh signaling pathway in P19 cells. Experimental & Molecular Medicine, 48(7), e248. Gu, Y., et al. (2013). miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chinese Medical Journal, 126(23), 4435–4439. Jentzsch, C., et al. (2012). A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. Journal of Molecular and Cellular Cardiology, 52(1), 13–20. Irani, S., & Hussain, M. M. (2015). Role of microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling and cancer. Current Opinion in Lipidology, 26(2), 139–146. Sayed, D., et al. (2007). MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Research, 100(3), 416–424. Duisters, R.F., et al. (2009). miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circulation Research, 104(2), 170–178. Chino, H., et al. (2016). Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer. Journal of Thoracic Disease, 8(9), 2646–2650.